On quantitative relationships between drug-like compound lipophilicity and plasma free fraction in monkey and human

Journal of Pharmaceutical Sciences

Volumn 101, Issue 3, 2012, Pages 1028-1039

  Zoghbi, Sami S ^a   Anderson, Kacey B ^a   Jenko, Kimberly J ^a   Luckenbaugh, David A ^a   Innis, Robert B ^a   Pike, Victor W ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Drug; Drug like properties; Lipophilicity; LogD; LogP; Physicochemical properties; Plasma free fraction; Protein binding; Radiotracer; Structure property relationship

Indexed keywords

1 [2 (4 FLUOROBENZAMIDO)ETHYL] 4 (7 METHOXY 1 NAPHTHYL)PIPERAZINE F 18; BUFFER; CUMI 101 C 11; DASB C 11; DLOP C 11; FBR F 18; FECNT F 18; FMPEP D2 F 18; LOPERAMIDE C 11; NOP 1A C 11; OCTANOL; PBR 01 C 11; PBR 28 C 11; PLASMA PROTEIN; ROLIPRAM C 11; RX 1 C 11; SL 702 F 18; SP 203 C 11; TRACER; UNCLASSIFIED DRUG; WAY C 11; XB 1 F 18;

ANIMAL TISSUE; ARTICLE; CORRELATION COEFFICIENT; FRACTIONATION; HUMAN; HUMAN TISSUE; HUMAN VERSUS ANIMAL COMPARISON; LIPOPHILICITY; MOLECULAR WEIGHT; NONHUMAN; PH; PHASE PARTITIONING; PLASMA; PLASMA FREE FRACTION; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; SPECIES DIFFERENCE; ULTRAFILTRATION;

EID: 84855907412     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22822     Document Type: Article

References (47)

1. Smith DA, van de Waterbeemd H, Walker DK. Pharmacokinetics and metabolism in drug design. 2001. Weinheim, Germany: Wiley VCH.
2. Schmidt S, Gonzalez D, Derendof H. 2010. Significance of protein binding in pharmacokinetics and pharmacodynamics. J Pharm Sci 99:1107-1122.
3. Waterhouse RN. 2003. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol 5:376-389.
4. Laruelle M, Slifstein M, Huang Y. 2003. Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mol Imaging Biol 5:363-375.
5. Pike VW. 2009. PET radiotracers: Crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol Sci 30:431-440.
6. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE. 2007. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533-1539.
7. Wilkinson GR. 1983. Plasma and tissue binding considerations in drug disposition. Drug Metab Rev 14:427-465.
8. Israeli ZH, Dayton PG. 2001. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev 33:161-235.
9. van de Waterbeeemd H, Gifford E. 2003. ADMET in silico modeling: Towards prediction paradise. Nat Rev Drug Discov 2:192-204.
10. Hall LM, Hall LH, Kier LB. 2009. Methods for predicting the affinity of drugs and drug-like compounds for human plasma proteins: A review. Curr Comput Aided Drug Des 5:90-105.
11. Leo A, Hansch C, Elkins D. 1971. Partition coefficients and their uses. Chem Rev 71:525-616.
12. Smith RN, Hansch C, Ames MM. 1975. Selection of a reference partitioning system for drug design work. J Pharm Sci 64:599-606.
13. Lázníček M, Květina J, Mazák J, Krch V. 1987. Plasma protein binding-lipophilicity relationships: Interspecies comparison of some organic acids. J Pharm Pharmacol 3:79-83.
14. van de Waterbeemd H, Smith DA, Jones BC. 2001. Lipophilicity in PK design: Methyl, ethyl, futile. J Comput Aided Mol Des 15:273-286.
15. Saiakhov RD, Stefan LR, Klopman G. 2000. Multiple computer-automated structure evaluation model of the plasma protein binding affinity of diverse drugs. Perspectives Drug Discovery Des 19:133-155.
16. Yamazaki K, Kanaoka M. 2004. Computational prediction of the plasma protein-binding percent of diverse pharmaceutical compounds. J Pharm Pharmacol 93:1480-1494.
17. Kratochwil NA, Huber W, Muller F, Kansy M, Gerber PR. 2002. Predicting plasma protein binding of drugs: A new approach. Biochem Pharmacol 64:1355-1374.
18. Lobell M, Sivarajah V. 2003. In silico prediction of aqueous solubility, human plasma protein binding and volume of distribution of compounds from calculated pKa and AlogP98 values. Mol Diversity 7:69-87.
19. Gleeson MP. 2007. Plasma protein binding affinity and its relationship to molecular structure: An in-silico analysis. J Med Chem 50:101-112.
20. 11C]2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1, 2, 4-triazine-3, 5(2H, 4H)dione in nonhuman primates. Eur J Nucl Med Mol Imaging 34:1050-1060.
21. 4 receptor ligands as prospective imaging probes for positron emission tomography. J Med Chem 53:7035-7047.
22. 11C]rolipram-PET. NeuroImage 26:1201-1210.
23. 18F-labeling of 3-fluoro-5-(2-(2-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile as a high affinity radioligand for imaging monkey brain metabotropic glutamate subtype-5 receptors with positron emission tomography. J Med Chem 50:3256-3266.
24. 11C]DASB positron emission tomography imaging of serotonin transporters in adolescent peer- and mother-reared rhesus monkeys. J Neurosci 26:4638-4643.
25. 1Areceptors in mice and monkey. NeuroImage 41:T157.
26. 11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function. J Med Chem 51:6034-6043.
27. 18F-FECNT: A polar radiometabolite confounds brain radioligand measurements. J Nucl Med 47:520-527.
28. 18F]XB-1 in monkey as a prospective histamine subtype 3 receptor PET radioligand. J Label Compd Radiopharm (in press) 54(Suppl. 1):S83.
29. 11C-labeled aryloxyanilide ligands for imaging brain peripheral benzodiazepine receptors in vivo. J Med Chem 51:17-30.
30. 11C-Loperamide and its N -desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux. J Nucl Med 49:649-656.
31. 1Areceptors with PET. Eur J Nucl Med Mol Imaging 34:1670-1682.
32. Pike VW, Rash KS, Chen Z, Pedregal C, Statnick MA, Kimura Y, Hong J, Zoghbi SS, Fujita M, Toledo MA, Diaz N, Gackenheimer SL, Tauscher JT, Barth VN, Innis RB. 2011. Synthesis and evaluation of radioligands for imaging brain nociceptin/orphanin FQ peptide (NOP) receptors with positron emission tomography. J Med Chem 54:2687-2700.
33. 11C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker. NeuroImage 49:2924-2932.
34. 18F-labeled ligand for imaging brain peripheral benzodiazepine receptors with PET. J Med Chem 52:688-699.
35. 1Areceptors. Curr Radiopharm 3:9-18.
36. Donohue SR, Krushinski JH, Pike VW, Chernet E, Phebus L, Chesterfield AK, Felder CC, Halldin C, Schaus JM. 2009. Synthesis, ex vivo evaluation, and radiolabeling of potent 1, 5-diphenylpyrrolidin-2-one cannabinoid subtype-1 receptor ligands as candidates for in vivo imaging. J Med Chem 51:5833-5842.
37. Clark J, Baldwin R, Bayne K, Brown MJ, Gebhart GF, Gonder JC, Gwathmey JK, Keeling ME, Kohn DF, Bobb JW, Smith OA, Steggerda JA-D, Van de Ber JL. 1996. Guide for the Care and Use of Laboratory Animals, Institute of Laboratory Animal Resources. Washington, DC: National Research Council.
38. Gandelman MS, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Innis RB. 1994. Evaluation of ultrafiltration for the free-fraction determination of single photon emission computed tomography (SPECT) radiotracers: ß-CIT, IBF, and iomazenil. J Pharm Sci 83:1014-1019.
39. Tetko IV, Poda GI. 2004. Application of ALOGPS 2.1 to predict logD distribution coefficient for Pfizer proprietary compounds. J Med Chem 47:5601-5604.
40. Acharya MR, Sparreboom A, Sausville EA, Conley BA, Doroshow JH, Venitz J, Figg WD. 2006. Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. Cancer Chemother Pharmacol 57:275-281.
41. Kratochwil NA, Huber W, Muller F, Kansy M, Gerber PR. 2004. Predicting plasma protein binding of drugs-revisited. Curr Opin Drug Discov Devel 7:507-511.
42. Kosa T, Maruyama T, Otagiri M. 1997. Species differences of serum albumins: I. Drug binding sites. Pharm Res 14:1607-1612.
43. Kosa T, Maruyama T, Otagiri M. 1998. Species differences of serum albumins: II. Chemical and thermal stability. Pharm Res 15:449-454.
44. Kosa T, Maruyama T, Sakai N, Yonemura N, Yahara S, Otagiri M. 1998. Species differences of serum albumins: III. Analysis of structural characteristics and ligand binding properties during N-B transitions. Pharm Res 15:592-598.
45. 1-acid glycoprotein in human, bovines and dogs. Drug Metab Pharmacokinet 17:300-306.
46. Goss KU, Bronner G. 2006. What is so special about the sorption behavior of highly fluorinated compounds? J Phys Chem A 110:9518-9522.
47. Bégué J-P, Bonnet-Delpon D. 2008. Bioorganic and medicinal chemistry of fluorine. New Jersey: John Wiley & Sons, Inc.